Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.

ABSTRACT: Chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen have shown positive responses in patients with multiple myeloma (MM). The phase 2 portion of the CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) included a cohort of Japanese patients with relapsed/refractory MM. Following a conditioning regimen of cyclophosphamide (300 mg/m² ) and fludarabine (30 mg/m² ), patients received a single cilta-cel infusion at a target dose of 0.75 × 10⁶ (range, 0.5-1.0 × 10⁶ CAR-positive viable T cells/kg). The primary endpoint was overall response rate (ORR; defined as partial response or better) by International Myeloma Working Group criteria. A key secondary endpoint was the rate of very good partial response (VGPR) or better (de

SUBMITTER: Ri M 

PROVIDER: S-EPMC9746030 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature